Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427742 | 1.00 | KCNQ2 (0.49) | KCNQ2AKR1C3AKR1C2CNR2CES2 | |
| SCHEMBL2395284 | 0.88 | AKR1C3 (0.46) | KCNQ2AKR1C3AKR1C2CNR2LMNA | |
| SCHEMBL20282765 | 0.86 | TAS1R3 (0.44) | KCNQ2AKR1C3AKR1C2CNR2CES2 | |
| SCHEMBL9587796 | 0.85 | KCNQ2 (0.49) | KCNQ2AKR1C3AKR1C2CNR2CES2 | |
| SCHEMBL10779187 | 0.84 | LMNA (0.51) | KCNQ2CNR2CES2CES1GAA | |
| SCHEMBL3364493 | 0.84 | KCNQ2 (0.48) | KCNQ2CNR2CES2CES1GAA | |
| SCHEMBL23886713 | 0.83 | CNR2 (0.46) | KCNQ2CNR2CES2CES1GAA | |
| SCHEMBL30370725 | 0.83 | CNR2 (0.46) | KCNQ2CNR2CES2CES1GAA | |
| SCHEMBL23886715 | 0.83 | CNR2 (0.46) | KCNQ2CNR2CES2CES1GAA | |
| SCHEMBL28563997 | 0.83 | MEN1 (0.46) | KCNQ2AKR1C3AKR1C2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104910045-A | Triad fullerene derivative and preparation method and application thereof | UNIV SOOCHOW | 2015-09-16 | — | — | CN | claimed |
| CN-101380317-B | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD | 2010-12-08 | — | — | CN | claimed |
| EP-2033635-A1 | Short-chain fatty acid derivatives for treating pruritus | Asan Laboratories Company (Cayman) Limited (CN) | 2009-03-11 | — | — | EP | claimed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | claimed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | claimed |
| US-5190946-A | Piperazine compounds restore sensitivity to drug resistant cancer cells | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | claimed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | claimed |
| CN-119639276-A | Ink composition, semiconductor nanoparticle-polymer composite prepared therefrom, electronic device, and display device | 三星电子株式会社 | 2025-03-18 | — | — | CN | disclosed |
| EP-3848364-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES AND INTERMEDIATES FOR THEIR PREPARATION | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| EP-3929197-B1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-3334736-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3683213-B1 | INTERMEDIATE FOR THE PREPARATION OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-10-12 | — | — | EP | disclosed |
| EP-3929197-A1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | disclosed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | disclosed |
| CN-1131390-A | Plaster containing -2- (p-fluorophenethyl) -3-fluoroallylamine for treating Alzheimer's disease | MERRELL DOW PHARMA (US) | 1996-09-18 | — | — | CN | disclosed |
| US-5190946-A | Piperazine compounds restore sensitivity to drug resistant cancer cells | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | disclosed |
| EP-0295604-A1 | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-12-21 | — | — | EP | disclosed |